{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T16:00:07Z","timestamp":1791734407193,"version":"4.3.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lasers Med Sci"],"DOI":"10.1007\/s10103-026-04849-w","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T03:58:16Z","timestamp":1776830296000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Photodynamic therapy with zinc phthalocyanine suppresses immune checkpoints in human melanoma cells"],"prefix":"10.1007","volume":"41","author":[{"given":"Mohammad Amin","family":"Doustvandi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoumeh","family":"Hajizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fateme","family":"Mohammadnejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negin","family":"Karamali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Hossein","family":"Yari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shima Alizadeh","family":"Nobari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behzad","family":"Baradaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"4849_CR1","doi-asserted-by":"publisher","unstructured":"Ingravallo G et al (2025) In: Cazzato G, Ingravallo G (eds) Epidemiology of Skin Cancer in 2024, in Skin Cancer - Past, Present and Future. Rijeka, IntechOpen. Editors. https:\/\/doi.org\/10.5772\/intechopen.1008698","DOI":"10.5772\/intechopen.1008698"},{"issue":"4","key":"4849_CR2","first-page":"63","volume":"9","author":"K Saginala","year":"2021","unstructured":"Saginala K et al (2021) Epidemiology of Melanoma. Med Sci 9(4):63","journal-title":"Med Sci"},{"issue":"3","key":"4849_CR3","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s40257-013-0025-9","volume":"14","author":"M Batus","year":"2013","unstructured":"Batus M et al (2013) Optimal management of metastatic melanoma: current strategies and future directions. Am J Clin Dermatol 14(3):179\u2013194","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"4849_CR4","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s40005-024-00698-3","volume":"55","author":"S Alizadeh Nobari","year":"2025","unstructured":"Alizadeh Nobari S et al (2025) Emerging trends in quantum dot-based photosensitizers for enhanced photodynamic therapy in cancer treatment. J Pharm Invest 55(1):55\u201390","journal-title":"J Pharm Invest"},{"key":"4849_CR5","doi-asserted-by":"publisher","first-page":"103515","DOI":"10.1016\/j.redox.2025.103515","volume":"80","author":"Q Guo","year":"2025","unstructured":"Guo Q et al (2025) Applications and enhancement strategies of ROS-based non-invasive therapies in cancer treatment. Redox Biol 80:103515","journal-title":"Redox Biol"},{"key":"4849_CR6","doi-asserted-by":"publisher","first-page":"103212","DOI":"10.1016\/j.pdpdt.2022.103212","volume":"41","author":"N Rajabi","year":"2023","unstructured":"Rajabi N et al (2023) Photodynamic therapy with zinc phthalocyanine enhances the anti-cancer effect of tamoxifen in breast cancer cell line: Promising combination treatment against triple-negative breast cancer? Photodiagn Photodyn Ther 41:103212","journal-title":"Photodiagn Photodyn Ther"},{"issue":"3","key":"4849_CR7","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/php.13253","volume":"96","author":"R Falk-Mahapatra","year":"2020","unstructured":"Falk-Mahapatra R, Gollnick SO (2020) Photodynamic Therapy and Immunity: An Update. Photochem Photobiol 96(3):550\u2013559","journal-title":"Photochem Photobiol"},{"issue":"7","key":"4849_CR8","doi-asserted-by":"publisher","first-page":"7239","DOI":"10.3390\/cimb46070430","volume":"46","author":"D Aebisher","year":"2024","unstructured":"Aebisher D, Przyg\u00f3rzewska A, Bartusik-Aebisher D (2024) The Latest Look at PDT and Immune Checkpoints. Curr Issues Mol Biol 46(7):7239\u20137257","journal-title":"Curr Issues Mol Biol"},{"key":"4849_CR9","doi-asserted-by":"publisher","first-page":"1335920","DOI":"10.3389\/fimmu.2024.1335920","volume":"15","author":"T Dudzik","year":"2024","unstructured":"Dudzik T, Doma\u0144ski I, Makuch S (2024) The impact of photodynamic therapy on immune system in cancer - an update. Front Immunol 15:1335920","journal-title":"Front Immunol"},{"issue":"1","key":"4849_CR10","doi-asserted-by":"publisher","first-page":"11667","DOI":"10.1038\/s41598-023-38862-8","volume":"13","author":"CS Lobo","year":"2023","unstructured":"Lobo CS et al (2023) Photodynamic therapy changes tumour immunogenicity and promotes immune-checkpoint blockade response, particularly when combined with micromechanical priming. Sci Rep 13(1):11667","journal-title":"Sci Rep"},{"issue":"4","key":"4849_CR11","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41568-022-00442-9","volume":"22","author":"S Kalaora","year":"2022","unstructured":"Kalaora S et al (2022) Mechanisms of immune activation and regulation: lessons from melanoma. Nat Rev Cancer 22(4):195\u2013207","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"4849_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11912-018-0676-z","volume":"20","author":"M Furue","year":"2018","unstructured":"Furue M et al (2018) Melanoma and Immune Checkpoint Inhibitors. Curr Oncol Rep 20(3):29","journal-title":"Curr Oncol Rep"},{"key":"4849_CR13","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.semcancer.2022.03.014","volume":"86","author":"S Gaikwad","year":"2022","unstructured":"Gaikwad S et al (2022) Immune checkpoint proteins: Signaling mechanisms and molecular interactions in cancer immunotherapy. Sem Cancer Biol 86:137\u2013150","journal-title":"Sem Cancer Biol"},{"key":"4849_CR14","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jphotobiol.2017.09.020","volume":"176","author":"MA Doustvandi","year":"2017","unstructured":"Doustvandi MA et al (2017) The interaction between the light source dose and caspase-dependent and-independent apoptosis in human SK-MEL-3 skin cancer cells following photodynamic therapy with zinc phthalocyanine: A comparative study. J Photochem Photobiol B 176:62\u201368","journal-title":"J Photochem Photobiol B"},{"key":"4849_CR15","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.pdpdt.2019.08.027","volume":"28","author":"MA Doustvandi","year":"2019","unstructured":"Doustvandi MA et al (2019) Photodynamic therapy using zinc phthalocyanine with low dose of diode laser combined with doxorubicin is a synergistic combination therapy for human SK-MEL-3 melanoma cells. Photodiagn Photodyn Ther 28:88\u201397","journal-title":"Photodiagn Photodyn Ther"},{"issue":"3","key":"4849_CR16","doi-asserted-by":"publisher","first-page":"202","DOI":"10.2174\/1570164611310030003","volume":"10","author":"A Bulman","year":"2013","unstructured":"Bulman A, Neagu M, Constantin C (2013) Immunomics in Skin Cancer - Improvement in Diagnosis, Prognosis and Therapy Monitoring. Curr Proteom 10(3):202\u2013217","journal-title":"Curr Proteom"},{"issue":"4","key":"4849_CR17","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252\u2013264","journal-title":"Nat Rev Cancer"},{"key":"4849_CR18","doi-asserted-by":"publisher","first-page":"153303381879179","DOI":"10.1177\/1533033818791795","volume":"17","author":"C Naidoo","year":"2018","unstructured":"Naidoo C, Kruger CA, Abrahamse H (2018) Photodynamic Therapy for Metastatic Melanoma Treatment: A Review. Technol Cancer Res Treat 17:1533033818791795","journal-title":"Technol Cancer Res Treat"},{"key":"4849_CR19","doi-asserted-by":"publisher","unstructured":"Ara\u00fajo JL et al (2023) Photodynamic Therapy Directed to Melanoma Skin Cancer by Thermosensitive Hydrogel Containing Chlorophyll A. 16. https:\/\/doi.org\/10.3390\/ph16121659. Pharmaceuticals","DOI":"10.3390\/ph16121659"},{"key":"4849_CR20","doi-asserted-by":"crossref","unstructured":"Cen Y et al (2025) Chimeric Peptide Functionalized Immunostimulant to Orchestrate Photodynamic Immunotherapeutic Effect by PD-L1 Deglycosylation and CD47 Inhibition. ACS Applied Materials & Interfaces","DOI":"10.1021\/acsami.4c22466"},{"issue":"1","key":"4849_CR21","doi-asserted-by":"publisher","first-page":"4647","DOI":"10.1038\/s41598-023-30256-0","volume":"13","author":"P Gurung","year":"2023","unstructured":"Gurung P et al (2023) Chlorin e6-associated photodynamic therapy enhances abscopal antitumor effects via inhibition of PD-1\/PD-L1 immune checkpoint. Sci Rep 13(1):4647","journal-title":"Sci Rep"},{"issue":"8","key":"4849_CR22","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1021\/acs.molpharmaceut.4c00254","volume":"21","author":"Z Fu","year":"2024","unstructured":"Fu Z et al (2024) Photodynamic Therapy Synergizes CD47 Blockade Strategy for Enhanced Antitumor Therapy. Mol Pharm 21(8):3897\u20133908","journal-title":"Mol Pharm"},{"issue":"12Supplement","key":"4849_CR23","doi-asserted-by":"publisher","first-page":"pLB061","DOI":"10.1158\/1538-7445.AM2022-LB061","volume":"82","author":"R Gorlick","year":"2022","unstructured":"Gorlick R et al (2022) Abstract LB061: Evaluation of the in vivo efficacy of the B7-H3 targeting antibody-drug conjugate (ADC) DS7300a: A report fro the Pediatric Preclinical In Vivo Resting (PIVOT) program. Cancer Res 82(12Supplement):pLB061\u2013LB061","journal-title":"Cancer Res"},{"issue":"5","key":"4849_CR24","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1097\/CMR.0000000000000281","volume":"26","author":"EAL Enninga","year":"2016","unstructured":"Enninga EAL et al (2016) Galectin-9 modulates immunity by promoting Th2\/M2 differentiation and impacts survival in patients with metastatic melanoma. Melanoma Res 26(5):429\u2013441","journal-title":"Melanoma Res"},{"issue":"1","key":"4849_CR25","doi-asserted-by":"publisher","first-page":"e005714","DOI":"10.1136\/jitc-2022-005714","volume":"11","author":"S Schlichtner","year":"2023","unstructured":"Schlichtner S et al (2023) T lymphocytes induce human cancer cells derived from solid malignant tumors to secrete galectin-9 which facilitates immunosuppression in cooperation with other immune checkpoint proteins. J Immunother Cancer 11(1):e005714","journal-title":"J Immunother Cancer"},{"key":"4849_CR26","doi-asserted-by":"crossref","unstructured":"Alzeibak R et al (2021) Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future. J Immunother Cancer, 9(1); p.e001926","DOI":"10.1136\/jitc-2020-001926"},{"issue":"12","key":"4849_CR27","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1002\/1878-0261.12851","volume":"14","author":"A Ahmed","year":"2020","unstructured":"Ahmed A, Tait SWG (2020) Targeting immunogenic cell death in cancer. Mol Oncol 14(12):2994\u20133006","journal-title":"Mol Oncol"},{"issue":"11","key":"4849_CR28","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/s41419-020-03221-2","volume":"11","author":"J Fucikova","year":"2020","unstructured":"Fucikova J et al (2020) Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death Dis 11(11):1013","journal-title":"Cell Death Dis"},{"issue":"16","key":"4849_CR29","doi-asserted-by":"publisher","first-page":"10135","DOI":"10.1021\/acs.chemrev.3c00161","volume":"123","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Doan B-T, Gasser G (2023) Metal-Based Photosensitizers as Inducers of Regulated Cell Death Mechanisms. Chem Rev 123(16):10135\u201310155","journal-title":"Chem Rev"},{"key":"4849_CR30","doi-asserted-by":"crossref","unstructured":"Allegra A et al (2020) Oxidative stress and photodynamic therapy of skin cancers: mechanisms, challenges and promising developments, vol 9. Antioxidants (Basel), 5","DOI":"10.3390\/antiox9050448"},{"key":"4849_CR31","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.freeradbiomed.2020.01.018","volume":"152","author":"F Valli","year":"2020","unstructured":"Valli F et al (2020) Crosstalk between oxidative stress-induced apoptotic and autophagic signaling pathways in Zn(II) phthalocyanine photodynamic therapy of melanoma. Free Radic Biol Med 152:743\u2013754","journal-title":"Free Radic Biol Med"},{"issue":"12","key":"4849_CR32","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nrc3380","volume":"12","author":"DV Krysko","year":"2012","unstructured":"Krysko DV et al (2012) Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 12(12):860\u2013875","journal-title":"Nat Rev Cancer"},{"key":"4849_CR33","doi-asserted-by":"publisher","first-page":"215350","DOI":"10.1016\/j.ccr.2023.215350","volume":"495","author":"M Warszy\u0144ska","year":"2023","unstructured":"Warszy\u0144ska M, Repetowski P, D\u0105browski JM (2023) Photodynamic therapy combined with immunotherapy: Recent advances and future research directions. Coord Chem Rev 495:215350","journal-title":"Coord Chem Rev"},{"issue":"1","key":"4849_CR34","doi-asserted-by":"publisher","first-page":"148","DOI":"10.7150\/thno.79367","volume":"13","author":"R Wang","year":"2023","unstructured":"Wang R et al (2023) Blockade of dual immune checkpoint inhibitory signals with a CD47\/PD-L1 bispecific antibody for cancer treatment. Theranostics 13(1):148\u2013160","journal-title":"Theranostics"},{"issue":"11","key":"4849_CR35","doi-asserted-by":"publisher","first-page":"12845","DOI":"10.1021\/acsami.0c20422","volume":"13","author":"Z Su","year":"2021","unstructured":"Su Z et al (2021) Dual-Sensitive PEG-Sheddable Nanodrug Hierarchically Incorporating PD-L1 Antibody and Zinc Phthalocyanine for Improved Immuno-Photodynamic Therapy. ACS Appl Mater Interfaces 13(11):12845\u201312856","journal-title":"ACS Appl Mater Interfaces"},{"issue":"1","key":"4849_CR36","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s12964-024-01555-4","volume":"22","author":"S Jin","year":"2024","unstructured":"Jin S et al (2024) Discovery of a novel small molecule as CD47\/SIRP\u03b1 and PD-1\/PD-L1 dual inhibitor for cancer immunotherapy. Cell Commun Signal 22(1):173","journal-title":"Cell Commun Signal"},{"key":"4849_CR37","doi-asserted-by":"crossref","unstructured":"Castro KADF et al (2022) The surprisingly positive effect of zinc-phthalocyanines with high photodynamic therapy efficacy of melanoma cancer. Front Chem 10(2022):825716","DOI":"10.3389\/fchem.2022.825716"},{"issue":"2","key":"4849_CR38","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/eji.201445289","volume":"46","author":"R Sottile","year":"2016","unstructured":"Sottile R et al (2016) HLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors. Eur J Immunol 46(2):409\u2013419","journal-title":"Eur J Immunol"}],"container-title":["Lasers in Medical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10103-026-04849-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10103-026-04849-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10103-026-04849-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T03:58:21Z","timestamp":1776830301000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10103-026-04849-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4849"],"URL":"https:\/\/doi.org\/10.1007\/s10103-026-04849-w","relation":{},"ISSN":["1435-604X"],"issn-type":[{"value":"1435-604X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"2 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"78"}}